Wall Street brokerages expect Viveve Medical Inc (NASDAQ:VIVE) to announce sales of $4.60 million for the current quarter, Zacks reports. Four analysts have provided estimates for Viveve Medical’s earnings, with the lowest sales estimate coming in at $4.37 million and the highest estimate coming in at $4.92 million. Viveve Medical reported sales of $4.07 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 13%. The firm is scheduled to issue its next earnings results on Wednesday, November 14th.
On average, analysts expect that Viveve Medical will report full-year sales of $21.61 million for the current financial year, with estimates ranging from $20.88 million to $22.17 million. For the next fiscal year, analysts forecast that the business will report sales of $32.39 million per share, with estimates ranging from $29.12 million to $33.95 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Thursday, August 9th. The company reported ($0.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.01. Viveve Medical had a negative return on equity of 551.85% and a negative net margin of 239.33%. The firm had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $4.97 million.
Separately, ValuEngine raised Viveve Medical from a “hold” rating to a “buy” rating in a report on Monday, July 2nd. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $9.20.
A number of hedge funds have recently added to or reduced their stakes in VIVE. Acuta Capital Partners LLC increased its stake in shares of Viveve Medical by 58.1% in the 1st quarter. Acuta Capital Partners LLC now owns 685,215 shares of the company’s stock valued at $2,508,000 after buying an additional 251,796 shares during the period. Spark Investment Management LLC acquired a new stake in shares of Viveve Medical in the 1st quarter valued at $208,000. RTW Investments LP increased its stake in shares of Viveve Medical by 11.9% in the 2nd quarter. RTW Investments LP now owns 2,861,023 shares of the company’s stock valued at $7,782,000 after buying an additional 303,464 shares during the period. Wexford Capital LP increased its stake in shares of Viveve Medical by 152.5% in the 1st quarter. Wexford Capital LP now owns 698,200 shares of the company’s stock valued at $2,555,000 after buying an additional 421,700 shares during the period. Finally, LMR Partners LLP acquired a new stake in shares of Viveve Medical in the 2nd quarter valued at $112,000. 61.95% of the stock is owned by hedge funds and other institutional investors.
VIVE stock traded down $0.23 during midday trading on Wednesday, reaching $3.10. 196,500 shares of the company’s stock traded hands, compared to its average volume of 377,541. Viveve Medical has a 1-year low of $1.60 and a 1-year high of $6.00. The stock has a market capitalization of $102.02 million, a price-to-earnings ratio of -1.47 and a beta of -0.30. The company has a debt-to-equity ratio of 3.42, a current ratio of 4.41 and a quick ratio of 4.00.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
Further Reading: Average Daily Trade Volume – What You Need to Know
Get a free copy of the Zacks research report on Viveve Medical (VIVE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.